Denise Lecossier
Overview
Explore the profile of Denise Lecossier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Battivelli E, Lecossier D, Clavel F, Hance A
PLoS One
. 2013 Jan;
8(1):e52434.
PMID: 23320071
Background: Because uncoating of the capsid is linked to reverse transcription, modifications that delay this process lead to the persistence in the cytoplasm of capsids susceptible to recognition by the...
2.
Battivelli E, Migraine J, Lecossier D, Yeni P, Clavel F, Hance A
J Virol
. 2011 Sep;
85(22):11846-54.
PMID: 21917976
Although laboratory-adapted HIV-1 strains are largely resistant to the human restriction factor TRIM5α (hTRIM5α), we have recently shown that some viruses carrying capsid (CA) sequences from clinical isolates can be...
3.
Battivelli E, Migraine J, Lecossier D, Matsuoka S, Perez-Bercoff D, Saragosti S, et al.
J Virol
. 2011 Jun;
85(15):7828-35.
PMID: 21632761
TRIM5α is a restriction factor that can block an early step in the retroviral life cycle by recognizing and causing the disassembly of incoming viral capsids, thereby preventing the completion...
4.
Battivelli E, Lecossier D, Matsuoka S, Migraine J, Clavel F, Hance A
J Virol
. 2010 Aug;
84(21):11010-9.
PMID: 20702630
HIV-1 infectivity is strongly restricted by TRIM5α from certain primate species but has been described as being only marginally susceptible to human TRIM5α. In this study, we evaluated the effects...
5.
Matsuoka S, Dam E, Lecossier D, Clavel F, Hance A
Retrovirology
. 2009 Mar;
6:21.
PMID: 19254360
Background: HIV-1 Gag proteins are essential for virion assembly and viral replication in newly infected cells. Gag proteins are also strong determinants of viral infectivity; immune escape mutations in the...
6.
Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, Hance A, et al.
J Virol
. 2006 Mar;
80(7):3679-83.
PMID: 16537639
Lentiviruses utilize two polypurine tracts for initiation of plus-strand viral DNA synthesis. We have examined to what extent human immunodeficiency virus type 1 plus-strand initiation at the central polypurine tract...
7.
Lecossier D, Shulman N, Morand-Joubert L, Shafer R, Joly V, Zolopa A, et al.
J Acquir Immune Defic Syndr
. 2004 Dec;
38(1):37-42.
PMID: 15608522
Salvage therapy with efavirenz is often ineffective in patients having failed nevirapine treatment, even when mutations associated with efavirenz resistance are not detected by standard population-based genotyping. The presence of...
8.
Charpentier C, Dwyer D, Mammano F, Lecossier D, Clavel F, Hance A
J Virol
. 2004 Mar;
78(8):4234-47.
PMID: 15047838
Human immunodeficiency virus type 1 (HIV-1) drug resistance results from the accumulation of mutations in the viral genes targeted by the drugs. These genetic changes, however, are commonly detected and...
9.
Lecossier D, Bouchonnet F, Clavel F, Hance A
Science
. 2003 May;
300(5622):1112.
PMID: 12750511
No abstract available.